3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline

    February 2025 in “ Advanced Healthcare Materials ”
    Xingyun Yang, Mara Artibani, Yongcheng Jin, Aneesh Aggarwal, Yujia Zhang, Sandra Muñoz-Galván, Ellina Mikhailova, Lena Rai, Nobina Mukherjee, Ravinash Krishna Kumar, Ashwag Albukhari, Shaohua Ma, Linna Zhou, Ahmed A. Ahmed, Hagan Bayley
    This study addresses the challenge of ovarian cancer relapse due to minimal residual disease (MRD) by developing 3D microtumors using microfluidics to model MRD ex vivo. These microtumors accurately represent the non-genetic heterogeneity and molecular signatures of ovarian cancer MRD, particularly highlighting the upregulation of fatty acid metabolism genes. The study demonstrates that these 3D microtumors respond to the fatty acid oxidation inhibitor perhexiline, suggesting their potential as a platform for testing and discovering new MRD-specific therapies for ovarian cancer.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results